Recent Quotes (30 days)

You have no recent quotes
chg | %

Stellar Biotechnologies Inc  

(Public, CVE:KLH)   Watch this stock  
Find more results for KLH
-0.53 (-6.14%)
Feb 9 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 8.04 - 8.10
52 week 6.50 - 14.33
Open 8.05
Vol / Avg. 1,390.00/2,385.00
Mkt cap 69.24M
P/E     -
Div/yield     -
EPS -1.00
Shares 8.45M
Beta 1.73
Inst. own     -
Feb 10, 2016
Q1 2016 Stellar Biotechnologies Inc Earnings Call - 1:30PM EST - Add to calendar
Feb 9, 2016
Q1 2016 Stellar Biotechnologies Inc Earnings Release (Estimated)
Dec 15, 2015
Q4 2015 Stellar Biotechnologies Inc Earnings Call
Dec 14, 2015
Q4 2015 Stellar Biotechnologies Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 294.13% -2267.90%
Operating margin -555.04% -1536.70%
EBITD margin - -1494.16%
Return on average assets 16.16% -73.43%
Return on average equity 20.28% -306.63%
Employees 23 -
CDP Score - -


332 E Scott St
PORT HUENEME, CA 93041-2939
United States - Map
+1-805-4882800 (Phone)
+1-805-4882889 (Fax)

Website links


Stellar Biotechnologies, Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades, formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer, immune disorders, Alzheimer's disease and inflammatory diseases, or it can be used as a finished, injectable product in the immunodiagnostic market for measuring immune response in patients and research settings.

Officers and directors

Frank R. Oakes Chairman of the Board, President, Chief Executive Officer
Age: 65
Kathi Niffenegger CPA Chief Financial Officer, Secretary
Age: 58
Catherine Brisson Ph.D. Chief Operating Officer
Age: 42
Tessie Mary Che Ph.D. Director
Age: 65
Daniel E. Morse Ph.D. Director
Age: 74
Gregory T. Baxter Independent Director
Age: 56
David L. Hill Ph.D. Independent Director
Age: 65
Mayank D. Sampat Independent Director
Age: 60